Lexicon Pharmaceuticals reported $49.8 million revenue for FY 2025, up 60% year-over-year, alongside a $50.3 million net loss.
Lexicon Pharmaceuticals reported $49.8 million in revenue for fiscal year 2025, a 60% increase from the prior year. The company, focused on gene science and precision medicine, recorded a net loss of $50.3 million despite the revenue growth.
The biotech firm’s debt-to-equity ratio stood at 0.6x as of December 2025, reflecting moderate leverage. Lexicon’s commercial product, INPEFA, drives its revenue, with additional income from licensing deals, including partnerships like Viatris for international markets.
Pfizer, by contrast, operates on a vastly larger scale, with a workforce of 75,000 and a presence in approximately 200 countries. The comparison highlights the differing risk and growth profiles of emerging biotech firms versus established pharmaceutical giants.